AgroChem Maks d.o.o. is the company with primary business in distribution of plant protection and related products. Up till now we have reached the second position on Croatian pesticide market. Our strategy is cooperation with international companies who do not have interest for establishing their own branch office and direct sale in our territory whom AgroChem provides with full technical, commercial, registration and marketing support. AgroChem MAKS d.o.o. operates as a group of experienced and proven professionals who promote and sell plant protection products.Our experts on the field are open for advices considering application of these products, taking into account adequate and well-timed application, economically acceptable combinations of products and respect for the environment. We are following latest trends, the world's leading technologies, while investing in expertise and competence of our staff to ensure quick and quality professional services. Basic vision and guiding of our company is to sell high quality and economically acceptable products to other distributers and agricultural producers on Croatian and neighboring markets.This train of thought and vision has received a confirmation and Agrochem Max has become a significant entity in the distribution of plant protection products with a tendency towards a successful future development and progress.
Ergomed provides clinical consulting, regulatory affairs, data management, and disease expertise.
Prilaz baruna Filipovica 29
Fidelta offers integrated drug discovery services spanning from medicinal chemistry, custom synthesis, assay development to efficacy and toxicology studies. Our established in vivo models focus on respiratory, inflammation, fibrosis, infectives and oncology.
Parexel provides bioequivalence studies as well as clinical services across Phase I to Phase III of drug development including dose escalation, drug-drug interaction, biomarkers, first-in-man studies, ADME, imaging, and clinical research services.
Prilaz baruna Filipovića 25
PLIVA provides finished dosage forms and the production of APIs.
The University of Rijeka was founded in 1973 as a logical expansion of higher education institutions in western Croatia whose roots date back to the 17th century when the Rijeka Jesuit gymnasium was established. From its founding it has undergone a series of transformations which were for the most part the result of changes brought on by the national higher education policies. Today the University integrates its constituents' functions and ensures their unified and harmonized activities. Its mission is dedicated to making strategic and development-oriented decisions on numerous issues regarding the functioning of the academic community and continued facilitation of international competitiveness in all areas of scientific, artistic and professional activities. Through active collaboration with the economic and business sector along with partnerships for community development the University endeavors to contribute toward the socio-cultural transition into a knowledge-based society. Its vision targets the inclusion of the University of Rijeka within the top 500 European Universities, thus it has committed itself to dynamic development which systematically facilitates mobility and the development of research careers while providing each individual with an opportunity to express their talents and entrepreneurial energy.
Worldwide Clinical Trials employs more than 1,600 professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia and Asia. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way.From Early Phase and Bioanalytical Sciences through Late Phase and post approval, we provide world-class, full-service drug development services. With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO.